FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947368991> ?p ?o ?g. }

• W2947368991 abstract "e12011 Background: Long-term efficacy in the extended adjuvant setting requires a long follow-up. In the ExteNET trial, neratinib was given for a year and invasive disease-free survival (iDFS) assessed at 2 and 5 years. In women with HER2+ hormone receptor positive (HR+) cancer who initiated neratinib, the observed difference in iDFS between neratinib and placebo at 5 years (4.5%) was greater than at 2 years (3.7%). The objective of these analyses was to extrapolate the effect of neratinib on iDFS beyond 5 years in patients with HER2+/HR+ early stage breast cancer who initiated treatment after receiving adjuvant trastuzumab. Methods: We analyzed the 5-year follow-up of the ExteNET trial using flexible spline-based parametric survival models to project iDFS risk at 10 years. Analyses included only HR+ patients. Several model specifications were explored including various combinations of the following variables: treatment as a time varying covariate, nodal status (0, 1-3, ≥4 nodes), and months from last trastuzumab treatment to randomization. The regression models included different combinations of interaction terms, either a proportional hazards or a proportional odds (PO) link function, and either 2 or 6 knots. The model fit was compared using Akaike Information Criterion (AIC). Results: In general, the fit statistics among the 16 models were comparable; however, the model with the lowest AIC included no interaction terms, 2 knots, and the PO link function. The mean iDFS event rate at 10 years was estimated to be 12.2% for neratinib and 18.9% for placebo for a difference of 6.8% (range across 16 models: 6.8%-7.8%). The recurrence rate and the difference between treatment groups were largest in women with ≥4 positive nodes. Conclusions: Based on these analyses, the projected 10-year difference in iDFS between placebo and neratinib patients seems likely to persist. However, because the data was limited to 5 years, we could not include the effect of hormonal therapy cessation. Also, low event rates in the node negative group may require longer follow-up to evaluate. In absence of longer-term data for neratinib, flexible parametric survival modeling of the iDFS suggests that the effect of neratinib therapy may remain stable." @default.
• W2947368991 created "2019-06-07" @default.
• W2947368991 creator A5014578175 @default.
• W2947368991 creator A5018773741 @default.
• W2947368991 creator A5024474312 @default.
• W2947368991 creator A5043292277 @default.
• W2947368991 creator A5072015843 @default.
• W2947368991 creator A5086242530 @default.
• W2947368991 date "2019-05-20" @default.
• W2947368991 modified "2023-09-26" @default.
• W2947368991 title "Modeling longer-term efficacy of neratinib in the extended adjuvant setting for early-stage breast cancer." @default.
• W2947368991 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e12011" @default.
• W2947368991 hasPublicationYear "2019" @default.
• W2947368991 type Work @default.
• W2947368991 sameAs 2947368991 @default.
• W2947368991 citedByCount "0" @default.
• W2947368991 crossrefType "journal-article" @default.
• W2947368991 hasAuthorship W2947368991A5014578175 @default.
• W2947368991 hasAuthorship W2947368991A5018773741 @default.
• W2947368991 hasAuthorship W2947368991A5024474312 @default.
• W2947368991 hasAuthorship W2947368991A5043292277 @default.
• W2947368991 hasAuthorship W2947368991A5072015843 @default.
• W2947368991 hasAuthorship W2947368991A5086242530 @default.
• W2947368991 hasConcept C121608353 @default.
• W2947368991 hasConcept C126322002 @default.
• W2947368991 hasConcept C143998085 @default.
• W2947368991 hasConcept C146357865 @default.
• W2947368991 hasConcept C151730666 @default.
• W2947368991 hasConcept C2777863537 @default.
• W2947368991 hasConcept C2779413316 @default.
• W2947368991 hasConcept C2779786085 @default.
• W2947368991 hasConcept C530470458 @default.
• W2947368991 hasConcept C71924100 @default.
• W2947368991 hasConcept C86803240 @default.
• W2947368991 hasConceptScore W2947368991C121608353 @default.
• W2947368991 hasConceptScore W2947368991C126322002 @default.
• W2947368991 hasConceptScore W2947368991C143998085 @default.
• W2947368991 hasConceptScore W2947368991C146357865 @default.
• W2947368991 hasConceptScore W2947368991C151730666 @default.
• W2947368991 hasConceptScore W2947368991C2777863537 @default.
• W2947368991 hasConceptScore W2947368991C2779413316 @default.
• W2947368991 hasConceptScore W2947368991C2779786085 @default.
• W2947368991 hasConceptScore W2947368991C530470458 @default.
• W2947368991 hasConceptScore W2947368991C71924100 @default.
• W2947368991 hasConceptScore W2947368991C86803240 @default.
• W2947368991 hasLocation W29473689911 @default.
• W2947368991 hasOpenAccess W2947368991 @default.
• W2947368991 hasPrimaryLocation W29473689911 @default.
• W2947368991 hasRelatedWork W121210528 @default.
• W2947368991 hasRelatedWork W1987913181 @default.
• W2947368991 hasRelatedWork W2032022811 @default.
• W2947368991 hasRelatedWork W2038044937 @default.
• W2947368991 hasRelatedWork W2042924702 @default.
• W2947368991 hasRelatedWork W2246982801 @default.
• W2947368991 hasRelatedWork W2332318203 @default.
• W2947368991 hasRelatedWork W2623022931 @default.
• W2947368991 hasRelatedWork W2734450758 @default.
• W2947368991 hasRelatedWork W2803633326 @default.
• W2947368991 hasRelatedWork W2805626925 @default.
• W2947368991 hasRelatedWork W2889861603 @default.
• W2947368991 hasRelatedWork W2947742205 @default.
• W2947368991 hasRelatedWork W3006576317 @default.
• W2947368991 hasRelatedWork W3042685191 @default.
• W2947368991 hasRelatedWork W3137982752 @default.
• W2947368991 hasRelatedWork W3138668637 @default.
• W2947368991 hasRelatedWork W3160986432 @default.
• W2947368991 hasRelatedWork W3167626350 @default.
• W2947368991 hasRelatedWork W3203810102 @default.
• W2947368991 isParatext "false" @default.
• W2947368991 isRetracted "false" @default.
• W2947368991 magId "2947368991" @default.
• W2947368991 workType "article" @default.